TISIDB

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm Cytoplasm, cytoskeleton Cell membrane Single-pass type I membrane protein Cell projection, lamellipodium Cell projection, filopodium ; SUBCELLULAR LOCATION: Soluble KIT ligand: Secreted.
Domain	PF02404 Stem cell factor
Function	Ligand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins.

> Gene Ontology [ TOP ]
Biological Process	GO:0001541 ovarian follicle development GO:0001667 ameboidal-type cell migration GO:0001755 neural crest cell migration GO:0001776 leukocyte homeostasis GO:0002262 myeloid cell homeostasis GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002685 regulation of leukocyte migration GO:0002687 positive regulation of leukocyte migration GO:0002761 regulation of myeloid leukocyte differentiation GO:0002763 positive regulation of myeloid leukocyte differentiation GO:0006260 DNA replication GO:0006275 regulation of DNA replication GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0007265 Ras protein signal transduction GO:0007548 sex differentiation GO:0008406 gonad development GO:0008584 male gonad development GO:0008585 female gonad development GO:0010623 programmed cell death involved in cell development GO:0014031 mesenchymal cell development GO:0014032 neural crest cell development GO:0014033 neural crest cell differentiation GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0022602 ovulation cycle process GO:0030099 myeloid cell differentiation GO:0030258 lipid modification GO:0030318 melanocyte differentiation GO:0030335 positive regulation of cell migration GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0033023 mast cell homeostasis GO:0033024 mast cell apoptotic process GO:0033025 regulation of mast cell apoptotic process GO:0033026 negative regulation of mast cell apoptotic process GO:0033028 myeloid cell apoptotic process GO:0033032 regulation of myeloid cell apoptotic process GO:0033033 negative regulation of myeloid cell apoptotic process GO:0033674 positive regulation of kinase activity GO:0035162 embryonic hemopoiesis GO:0035234 ectopic germ cell programmed cell death GO:0038034 signal transduction in absence of ligand GO:0040017 positive regulation of locomotion GO:0042698 ovulation cycle GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043473 pigmentation GO:0045137 development of primary sexual characteristics GO:0045634 regulation of melanocyte differentiation GO:0045636 positive regulation of melanocyte differentiation GO:0045637 regulation of myeloid cell differentiation GO:0045639 positive regulation of myeloid cell differentiation GO:0045740 positive regulation of DNA replication GO:0045860 positive regulation of protein kinase activity GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046545 development of primary female sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046578 regulation of Ras protein signal transduction GO:0046579 positive regulation of Ras protein signal transduction GO:0046660 female sex differentiation GO:0046661 male sex differentiation GO:0046834 lipid phosphorylation GO:0046854 phosphatidylinositol phosphorylation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048066 developmental pigmentation GO:0048070 regulation of developmental pigmentation GO:0048087 positive regulation of developmental pigmentation GO:0048511 rhythmic process GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0048762 mesenchymal cell differentiation GO:0048863 stem cell differentiation GO:0048864 stem cell development GO:0048872 homeostasis of number of cells GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050900 leukocyte migration GO:0050931 pigment cell differentiation GO:0050932 regulation of pigment cell differentiation GO:0050942 positive regulation of pigment cell differentiation GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051056 regulation of small GTPase mediated signal transduction GO:0051057 positive regulation of small GTPase mediated signal transduction GO:0051272 positive regulation of cellular component movement GO:0060485 mesenchyme development GO:0061458 reproductive system development GO:0070661 leukocyte proliferation GO:0070662 mast cell proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0070666 regulation of mast cell proliferation GO:0070668 positive regulation of mast cell proliferation GO:0071425 hematopoietic stem cell proliferation GO:0071887 leukocyte apoptotic process GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0072089 stem cell proliferation GO:0072091 regulation of stem cell proliferation GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:1902033 regulation of hematopoietic stem cell proliferation GO:1902035 positive regulation of hematopoietic stem cell proliferation GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000147 positive regulation of cell motility GO:2000648 positive regulation of stem cell proliferation
Molecular Function	GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005173 stem cell factor receptor binding GO:0008083 growth factor activity GO:0035004 phosphatidylinositol 3-kinase activity GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component	GO:0030027 lamellipodium GO:0030175 filopodium GO:0031252 cell leading edge GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04060 Cytokine-cytokine receptor interaction hsa04151 PI3K-Akt signaling pathway hsa04640 Hematopoietic cell lineage hsa04916 Melanogenesis
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-180292: GAB1 signalosome R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-199418: Negative regulation of the PI3K/AKT network R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1257604: PIP3 activates AKT signaling R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-1433559: Regulation of KIT signaling R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04640 Hematopoietic cell lineage
hsa04916 Melanogenesis

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-1433559: Regulation of KIT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KITLG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between KITLG and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
17885078	Colon Carcinoma	Inhibit immunity (T cell function)	Mice bearing tumor cells with SCF siRNA knockdown exhibited significantly reduced MDSC expansion and restored proliferative responses of tumor-infiltrating T cells. Furthermore, the prevention of MDSC accumulation in conjunction with immune activation therapy showed synergistic therapeutic effect when treating mice bearing large tumors.
24144734	Breast Carcinoma	Inhibit immunity	A functional c-Kit/Kit ligand (KitL) signalling network is required for tumour angiogenesis and growth, and therefore the c-Kit/KitL system might well be a suitable target for the cancer immunotherapy approach. DNA vaccination, interferes with tumour vessel formation and transplanted tumour growth in vivo. Histological analysis demonstrates that, while tumour cell proliferation and vessel stabilisation are impaired, vessel permeability is increased in mice that produce mbKitL-targeting antibodies.

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KITLG in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KITLG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.675	0.154
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.813	0.422
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.571	0.463
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.315	0.504
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.649	0.623
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.111	0.942
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.169	0.68
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.039	0.975
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.286	0.839
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.557	0.61
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.018	0.14
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.228	0.117

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KITLG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	7.4	-7.4	0.169
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KITLG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KITLG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KITLG. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KITLG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KITLG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KITLG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KITLG
Name	KIT ligand
Aliases	SCF; Kitl; KL-1; FPH2; stem cell factor; steel factor; familial progressive hyperpigmentation 2; FPHH; SHEP7 ......
Chromosomal Location	12q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KITLG collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KITLG